Seattle vaccine developer raises $18M in Series A

Seattle-based Immune Design has raised an impressive $18 million in its first round of venture capital. The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies. The company only has three full time staffers, but Immune Design says it will quickly expand to 30. And the developer has already attracted some top venture capital groups. Alta Partners, The Column Group and Versant Ventures all participated in the round.

- check out the company's release
- read the story from the Seattle Post-Intelligencer

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.